Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide
Objective To explore the role and underlying mechanism of microfibrillar associated protein 5 (MFAP5) in the treatment of overweight polycystic ovary syndrome (PCOS) with metformin combined with glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutides, by analyzing the correlation of the mo...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Third Military Medical University
2022-02-01
|
| Series: | Di-san junyi daxue xuebao |
| Subjects: | |
| Online Access: | http://aammt.tmmu.edu.cn/Upload/rhtml/202109129.htm |
| _version_ | 1819279061175762944 |
|---|---|
| author | LI Weixin LI Xing LI Xing LIAO Mingyu SHI Liu ZHANG Yuling PENG Guiliang HONG Pian LONG Min ZHENG Hongting |
| author_facet | LI Weixin LI Xing LI Xing LIAO Mingyu SHI Liu ZHANG Yuling PENG Guiliang HONG Pian LONG Min ZHENG Hongting |
| author_sort | LI Weixin |
| collection | DOAJ |
| description | Objective To explore the role and underlying mechanism of microfibrillar associated protein 5 (MFAP5) in the treatment of overweight polycystic ovary syndrome (PCOS) with metformin combined with glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutides, by analyzing the correlation of the molecule alteration with improvement of metabolic indexes. Methods Twenty-three overweight or obese PCOS patients who were treated with metformin combined with liraglutide for 12 weeks in our hospital during December 2019 and February 2021 were retrospectively enrolled. According to body mass index (BMI), the subjects were divided into obese group (n=12) and overweight group (n=11). They were all given oral administration of metformin hydrochloride enteric-coated tablet (0.5 g, 3 times/day) and subcutaneous injection of liraglutide injection (primarily, 0.6 mg, once/day, and then increased to 1.2 mg, once/day, 1 week later, with the maximum dose of 1.8 mg). Physical measurement indicators, metabolic and inflammatory related indicators and sex hormone levels of the 2 groups were collected before and after 12 weeks of treatment. Plasma MFAP5 level was detected by ELISA. Results After 12 weeks of treatment, physical measurement indicators, glucose and lipid metabolism indicators, inflammatory indicators and sex hormone levels were all improved in both groups (P < 0.05). Correlation analysis showed that the alteration of plasma MFAP5 level in all patients were positively correlated with the changes of body weight (r=0.520, P=0.011), BMI (r=0.469, P=0.024), waist circumference (r=0.634, P=0.001), hip circumference (r=0.587, P=0.001), fasting insulin (r=0.602, P=0.002) and triglyceride (r=0.556, P=0.002). For the patients form the overweight group, their change of plasma MFAP5 level had a positive correlation with the changes of glucolipid metabolism related indicators, including insulin at 60 min in insulin releasing test (r=0.602, P=0.002) and triglyceride (r=0.655, P=0.029). In the obese group, the change of plasma MFAP5 level was positively correlated with the changes of waist circumference (r=0.495, P=0.002), hip circumference (r=0.508, P=0.010), glucolipid metabolism related indicators, such as fasting insulin (r=0.578, P=0.001), insulin at 180 min (r=0.656, P=0.021), HOMA-IR (r=0.497, P=0.012), triglyceride (r=0.595, P=0.041), and sex hormone. Conclusion In overweight PCOS patients, plasma MFAP5 level is related to the improvement of glucolipid metabolism. MFAP5 may be a related molecule involved in the treatment of overweight PCOS with liraylutide combined with metformin, and may serve as a reliable indicator in monitoring of therapeutic efficacy. |
| first_indexed | 2024-12-24T00:21:55Z |
| format | Article |
| id | doaj.art-74858278d0274c7ea58feb60c206018d |
| institution | Directory Open Access Journal |
| issn | 1000-5404 |
| language | zho |
| last_indexed | 2024-12-24T00:21:55Z |
| publishDate | 2022-02-01 |
| publisher | Editorial Office of Journal of Third Military Medical University |
| record_format | Article |
| series | Di-san junyi daxue xuebao |
| spelling | doaj.art-74858278d0274c7ea58feb60c206018d2022-12-21T17:24:33ZzhoEditorial Office of Journal of Third Military Medical UniversityDi-san junyi daxue xuebao1000-54042022-02-0144321722310.16016/j.2097-0927.202109129Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutideLI Weixin0LI Xing1LI Xing2LIAO Mingyu3SHI Liu4ZHANG Yuling5PENG Guiliang6HONG Pian7 LONG Min8 ZHENG Hongting9Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, 210002, ChinaDepartment of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037Department of Endocrinology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037 Objective To explore the role and underlying mechanism of microfibrillar associated protein 5 (MFAP5) in the treatment of overweight polycystic ovary syndrome (PCOS) with metformin combined with glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutides, by analyzing the correlation of the molecule alteration with improvement of metabolic indexes. Methods Twenty-three overweight or obese PCOS patients who were treated with metformin combined with liraglutide for 12 weeks in our hospital during December 2019 and February 2021 were retrospectively enrolled. According to body mass index (BMI), the subjects were divided into obese group (n=12) and overweight group (n=11). They were all given oral administration of metformin hydrochloride enteric-coated tablet (0.5 g, 3 times/day) and subcutaneous injection of liraglutide injection (primarily, 0.6 mg, once/day, and then increased to 1.2 mg, once/day, 1 week later, with the maximum dose of 1.8 mg). Physical measurement indicators, metabolic and inflammatory related indicators and sex hormone levels of the 2 groups were collected before and after 12 weeks of treatment. Plasma MFAP5 level was detected by ELISA. Results After 12 weeks of treatment, physical measurement indicators, glucose and lipid metabolism indicators, inflammatory indicators and sex hormone levels were all improved in both groups (P < 0.05). Correlation analysis showed that the alteration of plasma MFAP5 level in all patients were positively correlated with the changes of body weight (r=0.520, P=0.011), BMI (r=0.469, P=0.024), waist circumference (r=0.634, P=0.001), hip circumference (r=0.587, P=0.001), fasting insulin (r=0.602, P=0.002) and triglyceride (r=0.556, P=0.002). For the patients form the overweight group, their change of plasma MFAP5 level had a positive correlation with the changes of glucolipid metabolism related indicators, including insulin at 60 min in insulin releasing test (r=0.602, P=0.002) and triglyceride (r=0.655, P=0.029). In the obese group, the change of plasma MFAP5 level was positively correlated with the changes of waist circumference (r=0.495, P=0.002), hip circumference (r=0.508, P=0.010), glucolipid metabolism related indicators, such as fasting insulin (r=0.578, P=0.001), insulin at 180 min (r=0.656, P=0.021), HOMA-IR (r=0.497, P=0.012), triglyceride (r=0.595, P=0.041), and sex hormone. Conclusion In overweight PCOS patients, plasma MFAP5 level is related to the improvement of glucolipid metabolism. MFAP5 may be a related molecule involved in the treatment of overweight PCOS with liraylutide combined with metformin, and may serve as a reliable indicator in monitoring of therapeutic efficacy.http://aammt.tmmu.edu.cn/Upload/rhtml/202109129.htmmetforminglucagon-like peptide-1 receptor agonistliraylutideoverweight polycystic ovary syndromeglucolipid metabolisimmicrofibrillar associated protein 5 |
| spellingShingle | LI Weixin LI Xing LI Xing LIAO Mingyu SHI Liu ZHANG Yuling PENG Guiliang HONG Pian LONG Min ZHENG Hongting Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide Di-san junyi daxue xuebao metformin glucagon-like peptide-1 receptor agonist liraylutide overweight polycystic ovary syndrome glucolipid metabolisim microfibrillar associated protein 5 |
| title | Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide |
| title_full | Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide |
| title_fullStr | Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide |
| title_full_unstemmed | Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide |
| title_short | Correlation between alteration of MFAP5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide |
| title_sort | correlation between alteration of mfap5 level and improvement of clinical indicators in patients with overweight polycystic ovary syndrome treated with metformin combined with liraglutide |
| topic | metformin glucagon-like peptide-1 receptor agonist liraylutide overweight polycystic ovary syndrome glucolipid metabolisim microfibrillar associated protein 5 |
| url | http://aammt.tmmu.edu.cn/Upload/rhtml/202109129.htm |
| work_keys_str_mv | AT liweixin correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT lixing correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT lixing correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT liaomingyu correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT shiliu correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT zhangyuling correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT pengguiliang correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT hongpian correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT longmin correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide AT zhenghongting correlationbetweenalterationofmfap5levelandimprovementofclinicalindicatorsinpatientswithoverweightpolycysticovarysyndrometreatedwithmetformincombinedwithliraglutide |